Search Results

GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic targets for a plethora of diseases. GPCRs also possess a pivotal role in the regulation of the physiological balance between healthy and pathological conditions; thus, their importance in systems biology cannot be underestimated. The molecular diversity of GPCR signaling systems is likely to be closely associated with disease-associated changes in organismal tissue complexity and compartmentalization, thus enabling a nuanced GPCR-based capacity to interdict multiple disease pathomechanisms at a systemic level. GPCRs have been long considered as controllers of communication between tissues and cells. This communication involves the ligand-mediated control of cell surface receptors that then direct their stimuli to impact cell physiology. Given the tremendous success of GPCRs as therapeutic targets, considerable focus has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors. In the past decade, however, attention has focused upon how stable multiprotein GPCR superstructures, termed receptorsomes, both at the cell surface membrane and in the intracellular domain dictate and condition long-term GPCR activities associated with the regulation of protein expression patterns, cellular stress responses and DNA integrity management. The ability of these receptorsomes (often in the absence of typical cell surface ligands) to control complex cellular activities implicates them as key controllers of the functional balance between health and disease. A greater understanding of this function of GPCRs is likely to significantly augment our ability to further employ these proteins in a multitude of diseases. Read full article

October 2022 "Background: Uncoupling proteins (UCPs) are unpaired electron carriers that uncouple oxygen intake by the electron transport chain from ATP production in the inner membrane of the mitochondria. The physiological activities of UCPs have been hotly contested, and the involvement of UCPs in the pathogenesis and progression of diabetes mellitus is among the greatest concerns. UCPs are hypothesised to be triggered by superoxide and then reduce mitochondrial free radical production, potentially protecting diabetes mellitus patients who are experiencing oxidative stress. Objectives: The objectives of the study are to find out the newest ways to treat diabetes mellitus through protein uncoupling." Read more at the source #DrGPCR #GPCR #IndustryNews

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4 WHIM syndrome is a rare immunodeficiency disorder that is characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. While several gain-of-function mutations that lead to C-terminal truncations, frame shifts and point mutations in the chemokine receptor CXCR4 have been identified in WHIM syndrome patients, the functional effect of these mutations are not fully understood. Here, we report on a new WHIM syndrome mutation that results in a frame shift within the codon for Ser339 (S339fs5) and compare the properties of S339fs5 with wild type CXCR4 and a previously identified WHIM syndrome mutant, R334X. The S339fs5 and R334X mutants exhibited significantly increased signaling compared to wild type CXCR4 including agonist-promoted calcium flux and extracellular signal-regulated kinase activation. This increase is at least partially due to a significant decrease in agonist-promoted phosphorylation, β-arrestin binding, and endocytosis of S339fs5 and R334X compared to wild type CXCR4. Interestingly, there were also significant differences in receptor degradation, with S339fs5 having a very high basal level of degradation compared to that of R334X and wild type CXCR4. In contrast to wild type CXCR4, both R334X and S339fs5 were largely insensitive to CXCL12-promoted degradation. Moreover, while basal and agonist-promoted degradation of wild type CXCR4 was effectively inhibited by the CXCR4 antagonist TE-14016, this had no effect on the degradation of the WHIM mutants. Taken together, these studies identify a new WHIM syndrome mutant, CXCR4-S339fs5, that promotes enhanced signaling, reduced phosphorylation, β-arrestin binding and endocytosis, and a very high basal rate of degradation that is not protected by antagonist treatment. Read full article

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Capital LLC, a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“ADSs”) at a gross purchase price of $6.50 per ADS, which is equivalent to CHF 1.00 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered warrants to purchase up to 9,230,772 shares in the form of 1,538,462 ADSs (the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares in the form of 913,095 ADSs (the “Unregistered Pre-Funded Warrants” and together with the Unregistered Warrants, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $6.50 per ADS, will become exercisable in 60 days after their date of issuance and will expire six years from their date of issuance. The Unregistered Pre-Funded Warrants have been funded to the amount of $6.49 with $0.01 payable on exercise." Read more at the source #DrGPCR #GPCR #IndustryNews

acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion

July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a healthcare-focused institutional investor, to sell 3,300,000 shares in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded Warrants”, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR #IndustryNews

The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million , including an investment of $3 million from Virtus Inspire Venture Partners.

In all these situations, chemokines interact with seven-transmembrane chemokine-type G protein-coupled In humans there are approximately 45 chemokines, 19 chemotactic or G-protein coupled chemokine receptors availability or to remove them from in vivo sites, while maintaining the responsiveness of canonical G J.; Graham, G. J., 2013). This study revealed that CCR2 scavenging is independent of G proteins, GRKs, arrestins, as well as clathrin

G protein-coupled receptors (GPCRs) are a vast family of membrane-bound proteins crucial for transmitting the initial GPCR-G protein association step, ensuring precise downstream signalling activation. avoiding interactions with non-cognate G proteins [1]. prepare the GPCR in a manner that optimizes subsequent cognate G protein activation. landscape where non-cognate G proteins play a critical preparatory role.

Mikel Garcia-Marcos for their work on Get ready to sharpen your tools:A short guide to heterotrimeric G Sokrat, Michel Bouvier, et al. for their study on the Role of the V2R-βarrestin-Gβγ complex in promoting G the chagas disease vector Rhodnius Prolixus (Stål) Role of the V2R-βarrestin-Gβγ complex in promoting G as Potential Drugs for Chronic Myeloid Leukemia Methods & Updates in GPCR Research High-throughput G GPCRs: Insights into Multi-Receptor Pharmacology for the Treatment of Metabolic Disease Relevance of G

Human cells express over 800 G-protein-coupled receptors (GPCRs) to facilitate communication with the Capturing the dynamics of GPCR activation has always been a challenge because G protein activation in Concurrently, the α1 helix extends, propagating structural changes throughout the G protein. Physiological roles of G protein-coupled receptor kinases and arrestins. Time-resolved cryo-EM of G-protein activation by a GPCR. Nature (2024).

Kenakin introduces the Hall model : a cube mapping allosteric and orthosteric interactions, layered with G a cooperativity constant : α:  Modulator’s effect on radioligand binding σ:  Modulator’s effect on G The G Protein Bottleneck: Why Stoichiometry Matters In a standout case study, Kenakin shows how G protein fails to reduce binding of a labeled NAM—not because of irreversibility, but because there isn’t enough G Add G protein. Suddenly, the agonist works .

One fascinating aspect of the cellular signaling network is the crosstalk between G protein-coupled receptors involvement in a myriad of physiological processes, mediate mostly signaling through heterotrimeric G this study was: How do growth factors, specifically through RTKs, modulate canonical heterotrimeric G The researchers focused on the phosphorylation of the G protein subunit Gαi at specific residues within Signaling Pathway Segregation: Phosphorylation events in the interdomain cleft and P loop uncouple G

G protein-coupled receptors (GPCRs) are integral membrane proteins crucial for sensing extracellular Central to GPCR function are G proteins, comprising subfamilies such as Gs, Gi/o, Gq/11, and G12/13, and a G protein detector tagged with an Nluc donor. Gilman, A.G., G proteins: transducers of receptor-generated signals.  Wan, Q., et al., Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. 

CXV: The Class F of G Protein-Coupled Receptors Yusman Manchanda, Dr. Alejandra Tomas, et al. for their research on Engineered mini-G proteins block the internalization of Jianming Han, Tao Che for their analysis of GPCR-G protein selectivity revealed by structural pharmacology Drs Christopher Langmead,  Gregory Stewart, et al. for their study on Molecular insights into orphan G GPCR Activation and Signaling GPCR-MAPK signaling pathways underpin fitness trade-offs in whitefly G

This concept is gaining significant attention in drug discovery, especially in the context of G protein-coupled However, GLP-1R can also engage other G proteins, such as Gi/o and Gq/11, leading to different downstream Additionally, GLP-1R couple to G protein-coupled receptor kinases (GRKs) and recruit β-arrestins, adding McNeill, S.M., et al., The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment Zhang, H., et al., Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic

G protein-coupled receptors (GPCRs) are membrane-bound proteins that sense external stimuli and relay As a result, dimerized SecR receptors exhibit higher rates of G protein activation and release, improving Bouvier, M., Oligomerization of G-protein-coupled transmitter receptors.   Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March Wootten, D., et al., Allostery and Biased Agonism at Class B G Protein-Coupled Receptors.  

This Week’s Highlights: G protein-coupled receptor (GPCR) pharmacogenomics Miles D Thompson , David Reiner-Link , Alessandro Berghella , Brinda K Rana , G Enrico Rovati , Valerie Capra , Caroline M Gorvin Joshua Levitz , Ben Jones , Johannes Broichhagen Design of allosteric modulators that change GPCR G Book a date with our Chief Match Maker! Direct line to the Dr. Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID-19 Signaling by neutrophil G

G., Lefkowitz, R. J., & Strader, C. D. (1986). G., & Schiöth, H. B. (2003). The G-protein-coupled receptors in the human genome form five main families. M., Pérez-Hernández, G., Batebi, H., Gao, Y., Eskici, G., Seven, A. W., & Skiniotis, G. (2023).

They manage this by interacting with G-proteins. What happens when a GPCR is activated? undergoes a conformational change to its active state (PDB ID: 3SN6); and (C) an active GPCR binds a G protein (PDB ID: 3SN6), which subsequently promotes nucleotide release from, and activation of, the G Orphan G protein-coupled receptors: The role in CNS disorders . Curr Issues Mol Biol. 2024 Oct 19;46(10):11646-11664. doi: 10.3390/cimb46100691   Navarro G, Sotelo E

al., for their work on Conformation- and activation-based BRET sensors differentially report on GPCR-G Samuel Liu, Preston Anderson, Sudarshan Rajagopal, Robert Lefkowitz, Howard Rockman for their review G scaffolding proteins required for Shh-mediated axon guidance GPCRs in Oncology and Immunology Regulator of G from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1 G protein coupling Reviews, GPCRs, and more Proteome-wide analysis reveals G protein-coupled receptor-like

Adhesion GPCRs A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer GPCR Activation and Signaling The TAS1R2 G-protein-coupled receptor is an ambient polymerase II degradation Growth factor-dependent phosphorylation of Gαi shapes canonical signaling by G protein-coupled receptors Kinetic Model for the Desensitization of G Protein-Coupled Receptor RNA-seq in mouse mammary epithelial cells GPCR Binders, Drugs, and more Structure-based identification of a G

intracellular trafficking of metabotropic glutamate receptor homo- and heterodimers Structural basis of G receptor CMKLR1 activation and signaling induced by a chemerin-derived agonist Functional profiling of the G Reporter Mouse Shows That TRPA1 Expression Is Largely Limited to Sensory Neuron Subsets Orphan peptide and G protein-coupled receptor signalling in alcohol use disorder GPCRs in Oncology and Immunology Regulator of G and Exhibition June 2 - 7, 2024 | Chemotactic Cytokines June 9 - 14, 2024 | 2024 Phosphorylation and G-Protein

of the N-Terminal Region for Novel Urotensin II Receptor Modulators GPCRs in Oncology and Immunology G preferred human codon-optimized clytin II gene in Chinese hamster ovary-K1 cells and its use in the G-protein-coupled Predicting the Hallucinogenic Potential of Molecules Using Artificial Intelligence Reviews, GPCRs, and more G receptor (GPCR) gene variants and human genetic disease Advances in yeast synthetic biology for human G Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million

Gonzalez-Hernandez, Hermany Munguba, Joshua Levitz for their work on Emerging modes of regulation of neuromodulatory G GPCR Activation and Signaling Emerging modes of regulation of neuromodulatory G protein-coupled receptors Astrocytic PAR1 and mGluR2/3 control synaptic glutamate time course at hippocampal CA1 synapses Regulator of G dorsolateral striatum of adult male mice Methods & Updates in GPCR Research RNA therapeutics in targeting G suppress hormones GPCR Events, Meetings, and Webinars June 9 - 14, 2024 | 2024 Phosphorylation and G-Protein

G protein-coupled receptor signaling analysis using homogenous time-resolved Förster resonance energy They activate several signaling pathways, via G proteins, β-arrestins, receptor tyrosine kinases, making Source: Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. References Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. G protein-coupled receptor signaling analysis using homogenous time-resolved Förster resonance energy

Garcia-Marcos for their work on Smooth operator(s): dialing up and down neurotransmitter responses by G-protein László Hunyady for their research on Functional consequences of spatial, temporal and ligand bias of G Fine-Tuning of GPCR Functions Smooth operator(s): dialing up and down neurotransmitter responses by G-protein regulators Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors cancer nanomedicines: from RNA sequencing data analysis to in vitro validation Signaling by Neutrophil G